SG10201808097QA - Stable sns-595 compositions and methods of preparation - Google Patents

Stable sns-595 compositions and methods of preparation

Info

Publication number
SG10201808097QA
SG10201808097QA SG10201808097QA SG10201808097QA SG10201808097QA SG 10201808097Q A SG10201808097Q A SG 10201808097QA SG 10201808097Q A SG10201808097Q A SG 10201808097QA SG 10201808097Q A SG10201808097Q A SG 10201808097QA SG 10201808097Q A SG10201808097Q A SG 10201808097QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
sns
preparation
stable
Prior art date
Application number
SG10201808097QA
Inventor
Anantha Sudhakar
Jeff Jacobs
Ahmad Hashash
Sean Ritchie
Hengqin Cheng
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of SG10201808097QA publication Critical patent/SG10201808097QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles. No Suitable Figure
SG10201808097QA 2009-09-04 2010-09-03 Stable sns-595 compositions and methods of preparation SG10201808097QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24016109P 2009-09-04 2009-09-04

Publications (1)

Publication Number Publication Date
SG10201808097QA true SG10201808097QA (en) 2018-10-30

Family

ID=42990341

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2014013163A SG2014013163A (en) 2009-09-04 2010-09-03 Stable sns-595 compositions and methods of preparation
SG2012014866A SG178956A1 (en) 2009-09-04 2010-09-03 Stable sns-595 compositions and methods of preparation
SG10201808097QA SG10201808097QA (en) 2009-09-04 2010-09-03 Stable sns-595 compositions and methods of preparation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2014013163A SG2014013163A (en) 2009-09-04 2010-09-03 Stable sns-595 compositions and methods of preparation
SG2012014866A SG178956A1 (en) 2009-09-04 2010-09-03 Stable sns-595 compositions and methods of preparation

Country Status (26)

Country Link
US (5) US8586601B2 (en)
EP (2) EP2674431A1 (en)
JP (3) JP6339315B2 (en)
KR (3) KR20170102568A (en)
CN (2) CN102596948B (en)
AU (1) AU2010289337B2 (en)
BR (1) BR112012004916A2 (en)
CA (2) CA3002440A1 (en)
CL (1) CL2012000565A1 (en)
CO (1) CO6511211A2 (en)
DK (1) DK2473507T3 (en)
EA (2) EA201270377A1 (en)
ES (1) ES2462502T3 (en)
HK (1) HK1172032A1 (en)
HR (1) HRP20140372T1 (en)
IL (3) IL218404A (en)
MX (1) MX2012002573A (en)
NZ (2) NZ598467A (en)
PH (1) PH12014500714B1 (en)
PL (1) PL2473507T3 (en)
PT (1) PT2473507E (en)
SG (3) SG2014013163A (en)
TW (2) TWI519535B (en)
UA (1) UA110465C2 (en)
WO (1) WO2011028979A1 (en)
ZA (1) ZA201201469B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2295056T3 (en) * 2004-03-15 2016-07-29 Sunesis Pharmaceuticals Inc Use of SNS-595 for treating leukemia
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
MX2010004350A (en) 2007-10-22 2010-05-19 Sunesis Pharmaceuticals Inc Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylam ino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-c arboxylic acid in combination therapy.
WO2009075841A2 (en) 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
AU2009335159B2 (en) 2008-12-31 2015-07-23 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6233176A (en) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd 1,4-dihydro-4-oxonaphthyridine derivative and salt thereof
SK281341B6 (en) 1994-06-14 2001-02-12 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JPH10173986A (en) 1996-12-16 1998-06-26 Sony Corp Mobile body image pickup device
JP4294121B2 (en) * 1998-06-05 2009-07-08 大日本住友製薬株式会社 Process for producing pyridonecarboxylic acid derivatives and intermediates thereof
JP4178783B2 (en) 2001-10-19 2008-11-12 三菱化学株式会社 Optical recording medium
PL2295056T3 (en) 2004-03-15 2016-07-29 Sunesis Pharmaceuticals Inc Use of SNS-595 for treating leukemia
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
HUE026693T2 (en) * 2006-08-02 2016-07-28 Sunesis Pharmaceuticals Inc Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
MX2010004350A (en) * 2007-10-22 2010-05-19 Sunesis Pharmaceuticals Inc Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylam ino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-c arboxylic acid in combination therapy.
WO2009075841A2 (en) * 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
AU2009335159B2 (en) 2008-12-31 2015-07-23 Sunesis Pharmaceuticals, Inc. Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
AU2010217796B2 (en) 2009-02-27 2015-04-30 Sunesis Pharmaceuticals, Inc. Methods of using SNS-595 for treatment of cancer subjects with reduced BRCA2 activity
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer

Also Published As

Publication number Publication date
US20190084978A1 (en) 2019-03-21
IL218404A (en) 2015-07-30
ES2462502T3 (en) 2014-05-23
DK2473507T3 (en) 2014-04-22
EA201400683A1 (en) 2015-05-29
IL218404A0 (en) 2012-04-30
PL2473507T3 (en) 2014-08-29
PH12014500714A1 (en) 2015-09-07
UA110465C2 (en) 2016-01-12
US9469635B2 (en) 2016-10-18
IL237724A (en) 2016-10-31
SG2014013163A (en) 2014-09-26
HRP20140372T1 (en) 2014-06-20
CN102596948B (en) 2015-07-22
US20110082169A1 (en) 2011-04-07
JP2013503899A (en) 2013-02-04
WO2011028979A1 (en) 2011-03-10
KR101811763B1 (en) 2017-12-22
US9969730B2 (en) 2018-05-15
JP6339315B2 (en) 2018-06-06
IL247929B (en) 2018-01-31
CN104177359B (en) 2018-06-01
KR20170102568A (en) 2017-09-11
AU2010289337A1 (en) 2012-03-22
NZ598467A (en) 2014-04-30
EP2473507B1 (en) 2014-03-19
AU2010289337B2 (en) 2014-10-30
PT2473507E (en) 2014-05-23
US20110086876A1 (en) 2011-04-14
JP2018127457A (en) 2018-08-16
CN102596948A (en) 2012-07-18
EA201270377A1 (en) 2013-01-30
PH12014500714B1 (en) 2015-09-07
US8138202B2 (en) 2012-03-20
ZA201201469B (en) 2013-05-29
NZ623780A (en) 2015-10-30
EP2674431A1 (en) 2013-12-18
SG178956A1 (en) 2012-04-27
CN104177359A (en) 2014-12-03
CO6511211A2 (en) 2012-08-31
US20170226104A1 (en) 2017-08-10
TWI615391B (en) 2018-02-21
CL2012000565A1 (en) 2012-12-07
TWI519535B (en) 2016-02-01
EP2473507A1 (en) 2012-07-11
HK1172032A1 (en) 2013-04-12
CA3002440A1 (en) 2011-03-10
US20140275547A1 (en) 2014-09-18
KR20180112103A (en) 2018-10-11
JP2016104769A (en) 2016-06-09
TW201504240A (en) 2015-02-01
US8586601B2 (en) 2013-11-19
KR20120078711A (en) 2012-07-10
BR112012004916A2 (en) 2017-07-04
TW201114767A (en) 2011-05-01
CA2772291A1 (en) 2011-03-10
MX2012002573A (en) 2012-04-10

Similar Documents

Publication Publication Date Title
PH12014500714A1 (en) Stable sns-595 compositions and methods of preparation
MX353035B (en) Delivery particles.
MX358448B (en) Delivery particles.
MX2019012939A (en) Linaclotide-containing formulations for oral administration.
EP2459707A4 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
MX354698B (en) Delivery particle.
IL226377B (en) Nanoparticle isoflavone compositions & methods of making and using the same
MX2013007611A (en) Methods for cryopreserving and encapsulating cells.
MX2013001677A (en) Stable formulations of linaclotide.
EP2556163A4 (en) High mannose glycans
MX2013007057A (en) Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans.
WO2011093832A3 (en) Stable efervescent formulations comprising cefaclor
HK1184181A1 (en) POLYETHERAMINES, COMPOSITIONS INCLUDING POLYETHERAMINES, AND METHODS OF g MAKING
IN2009DN08217A (en)
PL3210991T3 (en) Crystalline form of levoisovalerylspiramycin ii and preparations, preparation methods and uses thereof
IN2012DN03404A (en)
PL2582359T3 (en) Solid compositions in form of powders or granulates for the oral administration of active ingredients and method for obtaining them
MX2012010127A (en) Derivatives of aminoindanes, their preparation and their application in therapeutics.
IL222343A0 (en) Compositions comprising allogeneic th1 cells and uses thereof
EP2655607A4 (en) Methods and compositions for producing active vitamin k-dependent proteins
IL214211A0 (en) Stable vaccine compositions and methods for preparing the same
EP2566485A4 (en) Immunostimulatory compositions and methods of use thereof
IL224191A (en) Formulations of 14 -epi-analogues of vitamin d and cmc
MX2012007283A (en) Vaccine compositions.
ZA201105443B (en) Novel saponin compounds,methods of preparation thereof,use thereof and pharmaceutical compositions